HC Wainwright & Co. Downgrades NeuroSense Therapeutics to Neutral
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsDowngrades
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Lander Egaña Gorroño downgrades NeuroSense Therapeutics (NASDAQ:NRSN) from Buy to Neutral.
HC Wainwright & Co. analyst Lander Egaña Gorroño downgrades NeuroSense Therapeutics (NASDAQ:NRSN) from Buy to Neutral.
